Octanine (Human Coagulation Factor Ix)

Octanine is used in the management of inherited bleeding disorders that involve factor IX deficiency. It is indicated for:

• Hemophilia B: Provides temporary replacement of factor IX to prevent or control bleeding.
• Perioperative management: Supplies factor IX to maintain hemostasis during surgery or invasive procedures.
• Trauma‑related bleeding: Restores factor IX levels to achieve hemostasis in acute bleeding events.
• Congenital factor IX deficiency (non‑hemophilic): Supplements low endogenous factor IX levels.
• Acquired inhibitor‑related bleeding: Bypasses inhibitors to re‑establish clotting function.
• Prophylactic therapy: Regular infusions to reduce the frequency of spontaneous bleeds.

• Octanine contains recombinant human coagulation factor IX, which binds to activated factor X on platelet surfaces, forming the intrinsic tenase complex. This complex accelerates the conversion of factor X to factor Xa, leading to thrombin generation and fibrin clot formation, thereby restoring the deficient clotting activity in hemophilia B patients.

Adverse reactions to Octanine may vary in frequency and severity.

Common Side Effects

• Headache
• Fever
• Nausea
• Mild infusion site erythema
• Transient increase in liver enzymes
• Fatigue

Serious or Rare Side Effects

• Anaphylactic reaction
• Development of neutralizing antibodies (inhibitors)
• Thromboembolic events
• Severe hypersensitivity
• Acute hemolysis
• Renal impairment

Octanine should be used under careful clinical supervision, with attention to individual patient risk factors.

• Dosing individualisation: Adjust dose based on factor IX activity levels and clinical response.
• Monitoring: Regular laboratory assessment of factor IX activity and inhibitor screening.
• Infection risk: Observe for signs of viral transmission despite viral inactivation steps.
• Pregnancy and lactation: Use only if clearly indicated and benefits outweigh risks.
• Pediatric use: Dose adjustments may be required for children.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octanine may interact with other agents that affect coagulation or immune response.

Major Interactions (Avoid)

• Activated pro‑thrombin complex concentrates (aPCC): May increase risk of thrombosis.
• High‑dose factor VIIa: Combined use can lead to excessive clot formation.

Moderate Interactions (Monitor Closely)

• Antifibrinolytics (e.g., tranexamic acid): May enhance clot stability, requiring dose adjustment.
• Immunosuppressive agents: Potential impact on inhibitor development.
• Vaccines: Monitor for altered immune response.
• Antibiotics with renal clearance: May affect factor IX clearance.
• Concomitant anticoagulants: May counteract therapeutic effect of Octanine.